Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve block vs. painkiller: which works better for obese patients after chest surgery?

NCT ID NCT07391475

Symptom relief Sponsor: Zagazig University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two ways to manage pain after video-assisted chest surgery in 102 obese patients. One group received an ultrasound-guided nerve block (erector spinae plane block) with bupivacaine, while the other group got an intravenous painkiller (nalbuphine). The goal was to see which method provides longer-lasting pain relief and reduces the need for extra pain medication. The trial is complete and results will help guide pain management in this specific patient group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bupivacaine (nerve block) and Nalbuphine (intravenous painkiller)
What this could lead to
If the nerve block works better, it could offer a safer, more effective way to manage pain after chest surgery in obese patients, reducing the need for strong painkillers.
What could go wrong
This is a small, single-center study. The nerve block may not provide better pain relief than the standard drug, and there are risks like infection or bleeding from the injection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

102 people

The number who actually took part.

Started

Jul 2025

Finished

Jan 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * American Society of Anesthesiologist (ASA) status of II and III, * age between 21 years and 60 years * BMI (body mass index) between 30 and 40 kg/ m2 Exclusion Criteria: * BMI \<30 or \> 40 kg/ m2 * chronic pain with regular use of either opioids or gabapentinoids during the 2 weeks before surgery * history of thoracic surgery on the same side * anticipated high risk of conversion to thoracotomy * taking anticoagulation * suffering from any bleeding disorders * known allergy to local anesthetics, nalbuphine or fentanyl * active infection at the injection site * pre-existing neurological or psychiatric illness * severe cardiovascular disease * liver failure * renal failure (estimated glomerular filtration rate less than 15 ml min) * pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postoperative pain management are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postoperative pain management

Contacts and locations

Locations

  • ZagazigU

    Zagazig, Zagazig, 055, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.